Wright, DavidPoon, Liona CRolnik, Daniel LSyngelaki, ArgyroDelgado, Juan LuisVojtassakova, Denisade Alvarado, MercedesKapeti, EvgeniaRehal, AnoopPazos, AndreaCarbone, Ilma FlorianaDutemeyer, VivienPlasencia, WalterPapantoniou, NikosNicolaides, Kypros H2023-01-252023-01-252017-09-06http://hdl.handle.net/10668/11568The Aspirin for Evidence-Based Preeclampsia Prevention trial was a multicenter study in women with singleton pregnancies. Screening was carried out at 11-13 weeks' gestation with an algorithm that combines maternal factors and biomarkers (mean arterial pressure, uterine artery pulsatility index, and maternal serum pregnancy-associated plasma protein A and placental growth factor). Those with an estimated risk for preterm preeclampsia of >1 in 100 were invited to participate in a double-blind trial of aspirin (150 mg/d) vs placebo from 11-14 until 36 weeks' gestation. Preterm preeclampsia with delivery at 1 in 100 were invited to participate in a double-blind trial of aspirin (150 mg/d) vs placebo from 11-14 until 36 weeks' gestation. Preterm preeclampsia with delivery at We sought to examine the influence of compliance on the beneficial effect of aspirin in prevention of preterm preeclampsia in the Aspirin for Evidence-Based Preeclampsia Prevention trial. This was a secondary analysis of data from the trial. The proportion of prescribed tablets taken was used as an overall measure of compliance. Logistic regression analysis was used to estimate the effect of aspirin on the incidence of preterm preeclampsia according to compliance of Preterm preeclampsia occurred in 5/555 (0.9%) participants in the aspirin group with compliance ≥90%, in 8/243 (3.3%) of participants in the aspirin group with compliance The beneficial effect of aspirin in the prevention of preterm preeclampsia appears to depend on compliance.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Aspirin for Evidence-Based Preeclampsia Prevention trialaspirincompliancefirst-trimester screeningmean arterial blood pressureplacental growth factorpredictionpreeclampsiapregnancy-associated plasma protein Apyramid of pregnancy caretreatment effectuterine artery DopplerAdultAspirinDouble-Blind MethodEthnicityEvidence-Based MedicineFemaleHumansLogistic ModelsMaternal AgeMedication AdherencePlacenta Growth FactorPlatelet Aggregation InhibitorsPre-EclampsiaPregnancyPregnancy Trimester, FirstPregnancy-Associated Plasma Protein-APremature BirthPulsatile FlowRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsSmokingTreatment OutcomeUterine ArteryYoung Adultresearch article28888591open access10.1016/j.ajog.2017.08.1101097-6868https://kclpure.kcl.ac.uk/portal/files/77665877/ASPRE_trial_influence_of_WRIGHT_Accepted31August2017_GREEN_AAM.pdf